Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Burns

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
The Journal of Endocrinology|February 7, 2007
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetesThomas H Claus, Clark Q Pan, Joanne M Buxton, et al.
World Journal of Clinical Oncology|March 1, 2019
Impact of conditioning regimen on peripheral blood hematopoietic cell transplantMichael Burns, Anurag K Singh, Carrie C Hoefer, et al.
The Journal of Physical Chemistry. B|May 27, 2016
Molecular MRI in the Earth's Magnetic Field Using Continuous Hyperpolarization of a Biomolecule in WaterPhilipp Rovedo, Stephan Knecht, Tim Bäumlisberger, et al.
Journal of Medicinal Chemistry|February 6, 2007
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacyJoachim Rudolph, Libing Chen, Dyuti Majumdar, et al.
Cancer Journal (Sudbury, Mass.)|September 4, 2003
Neural stem cell biology may be well suited for improving brain tumor therapiesStephen Yip, Karen S Aboody, Michael Burns, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohortAlexandra Mack, Trung Duong Tran, Emelie Berglund, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 3, 2015
Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resectionChao-Hui Zuo, Man Xia, Jing-Shi Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2006
Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonistsLouis-David Cantin, Sidney Liang, Herbert Ogutu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Endocrinology|February 7, 2007
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetesThomas H Claus, Clark Q Pan, Joanne M Buxton, et al.
World Journal of Clinical Oncology|March 1, 2019
Impact of conditioning regimen on peripheral blood hematopoietic cell transplantMichael Burns, Anurag K Singh, Carrie C Hoefer, et al.
The Journal of Physical Chemistry. B|May 27, 2016
Molecular MRI in the Earth's Magnetic Field Using Continuous Hyperpolarization of a Biomolecule in WaterPhilipp Rovedo, Stephan Knecht, Tim Bäumlisberger, et al.
Journal of Medicinal Chemistry|February 6, 2007
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacyJoachim Rudolph, Libing Chen, Dyuti Majumdar, et al.
Cancer Journal (Sudbury, Mass.)|September 4, 2003
Neural stem cell biology may be well suited for improving brain tumor therapiesStephen Yip, Karen S Aboody, Michael Burns, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohortAlexandra Mack, Trung Duong Tran, Emelie Berglund, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 3, 2015
Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resectionChao-Hui Zuo, Man Xia, Jing-Shi Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2026
Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction CancerJohn H Strickler, Judith Raimbourg, Jonathan E Cohen, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2006
Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonistsLouis-David Cantin, Sidney Liang, Herbert Ogutu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Pageof 5